PGP and non-small cell lung carcinoma: Similarly, as an inhibitor of P-gp and BCRP, elacridar could inhibit the efflux of tyrosine kinase inhibitor erlotinib, resulting in improved efficacy against non-small-cell lung cancer (NSCLC) brain metastasis in nonhuman primate male Papio anubis baboons [11].